Janus kinase (JAK) inhibitors are a group of immune-modulating medications used to treat a variety of inflammatory diseases, including inflammatory bowel disease (IBD).
One JAK inhibitor, upadacitinib (Rinvoq), is approved by the Food and Drug Administration (FDA) for Crohn’s disease. Both upadacitinib and tofacitinib (Xeljanz) have approval for the treatment of ulcerative colitis, which is another form of IBD.
In addition, tofacitinib is under investigation specifically for the treatment of Crohn’s disease.
This interactive treatment guide explores how JAK inhibitors work to manage inflammation in IBD, including the emerging research on the use of these medications in Crohn’s disease.